A MicroRNA-7/growth Arrest Specific 6/TYRO3 Axis Regulates the Growth and Invasiveness of Sorafenib-resistant Cells in Human Hepatocellular Carcinoma

Overview

Journal Hepatology

Specialty Gastroenterology

Date 2017 Aug 24

PMID 28833396

Citations 66

Authors

Tasnuva D Kabir

Clarissa Ganda

Rikki M Brown

Dianne J Beveridge

Kirsty L Richardson

Vishal Chaturvedi

Patrick Candy

Michael Epis

Larissa Wintle

Felicity Kalinowski

Christina Kopp

Lisa M Stuart

George C Yeoh

Jacob George

Peter J Leedman

Affiliations

Soon will be listed here.

Abstract

Conclusion: We identified a mechanism for acquiring SR in HCC that is through the aberrant expression of the TYRO3/phosphoinositide 3-kinase/protein kinase B signal transduction pathway, and that can be overcome by miR-7 overexpression. Taken together, these data suggest a potential role for miR-7 as an RNA-based therapeutic to treat refractory and drug-resistant HCC. (Hepatology 2018;67:216-231).

Citing Articles

Resistance to Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma (HCC): Clinical Implications and Potential Strategies to Overcome the Resistance.

Gawi Ermi A, Sarkar D Cancers (Basel). 2024; 16(23).

PMID: 39682130 PMC: 11640171. DOI: 10.3390/cancers16233944.

Network pharmacology and bioinformatic integrative analysis reveals candidate gene targets and potential therapeutic of East Kalimantan propolis against hepatocellular carcinoma.

Kustiawan P, Siregar K, Jauhar M, Ramadhan D, Mardliyati E, Syaifie P Heliyon. 2024; 10(21):e39142.

PMID: 39524833 PMC: 11544044. DOI: 10.1016/j.heliyon.2024.e39142.

Delivery of Avocado Seed Extract Using Novel Charge-Switchable Mesoporous Silica Nanoparticles with Galactose Surface Modified to Target Sorafenib-Resistant Hepatocellular Carcinoma.

Basu A, Sae-Be A, Namporn T, Suriyaphan O, Sithisarn P, Leanpolchareanchai J Int J Nanomedicine. 2024; 19:10341-10365.

PMID: 39430309 PMC: 11488512. DOI: 10.2147/IJN.S478574.

MicroRNAs in Hepatocellular Carcinoma Pathogenesis: Insights into Mechanisms and Therapeutic Opportunities.

Mahboobnia K, Beveridge D, Yeoh G, Kabir T, Leedman P Int J Mol Sci. 2024; 25(17).

PMID: 39273339 PMC: 11395074. DOI: 10.3390/ijms25179393.

MerTK Drives Proliferation and Metastatic Potential in Triple-Negative Breast Cancer.

Iida M, Crossman B, Kostecki K, Glitchev C, Kranjac C, Crow M Int J Mol Sci. 2024; 25(10).

PMID: 38791148 PMC: 11121248. DOI: 10.3390/ijms25105109.